STOCK TITAN
  1. Home
  2. News
  3. ARWR

Arrowhead Pharmaceuticals Inc. - ARWR STOCK NEWS

Welcome to our dedicated news page for Arrowhead Pharmaceuticals (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arrowhead Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arrowhead Pharmaceuticals's position in the market.

News
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. presented final data from the Phase 2 SHASTA-2 study of plozasiran, showing significant reductions in triglycerides and APOC3 in patients with severe hypertriglyceridemia. Promising results led to the initiation of Phase 3 studies SHASTA-3 and SHASTA-4. Plozasiran demonstrated dose-dependent reductions in triglycerides and APOC3, with up to 86% and 90% reductions, respectively, and significant improvements in atherogenic lipoprotein levels. Over 90% of patients achieved triglyceride levels below the pancreatitis risk threshold, and almost half reached normal levels. Safety profile was favorable, with common adverse events like COVID-19 infection and diarrhea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) granted 31,700 restricted stock units to 32 new employees as an inducement for employment. The grants, approved under NASDAQ Listing Rules, vest annually over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
-
News
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. initiates Expanded Access Program for plozasiran in patients with familial chylomicronemia syndrome. New SHASTA-2 Phase 2 clinical data to be presented at ACC.24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences clinical trial
News
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) initiates Phase 1/2a study for ARO-DM1 in patients with type 1 myotonic dystrophy. ARO-DM1 shows promise in reducing DMPK expression and correcting spliceopathies, potentially improving muscle strength and function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
clinical trial
-
News
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to participate in upcoming events like TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. The company will engage in Fireside Chat Presentations on March 6 and March 13, 2024, respectively. Interested parties can access presentation materials on the Arrowhead website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
conferences
-
News
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) announced its fiscal 2024 Q1 results, revealing a net loss of $132.9 million, a significant increase from the previous year. The company is focusing on cardiometabolic and pulmonary verticals, with plans to reduce operating cash burn by $100 million. They also terminated development of two programs, ARO-SOD1 and HZN-457, and strengthened their balance sheet through a $450 million stock offering. Financially, the company's cash, cash equivalents, and restricted cash decreased to $58.2 million from $110.9 million in the previous quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
earnings
News
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Investors may access a live audio webcast on the Company's website. A replay of the webcast will be available. For analysts that wish to participate in the conference call, please register to receive the dial-in number and a personalized PIN code.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
conferences earnings
-
News
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) closed an underwritten registered offering of 15,790,000 shares of its Common Stock at $28.50 per share, generating approximately $450.0 million in gross proceeds. The company intends to allocate the net proceeds for research and development, general corporate expenses, and working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announces the pricing of an underwritten registered offering of 15,790,000 shares of its common stock at $28.50 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
offering
News
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) approved 'inducement' grants to 32 new employees, entitling them to receive up to 53,700 restricted stock units outside the stockholder-approved equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ARWR logo
Arrowhead Pharmaceuticals Inc.

Nasdaq:ARWR

ARWR Rankings

#1602 Ranked by Market Cap
#3965 Ranked by Stock Gains
N/A Ranked by Dividends

ARWR Stock Data

2.93B
118.95M
4.49%
66.68%
7.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Pasadena

About ARWR

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing